Tandem Investment Advisors Inc. Has $5.83 Million Position in IDEXX Laboratories, Inc. $IDXX

Tandem Investment Advisors Inc. cut its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,376 shares of the company’s stock after selling 1,009 shares during the quarter. Tandem Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $5,830,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Wormser Freres Gestion increased its position in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 1.5%

IDEXX Laboratories stock opened at $567.44 on Friday. The firm has a market cap of $44.76 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 3.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $513.02 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a 50 day moving average price of $554.49 and a two-hundred day moving average price of $599.94.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the firm posted $2.91 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on IDXX. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.